Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Healthcare Biotechnology
Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Noxopharm Ltd > NIOGOLD COMPLETES $2.5 FINANCING
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by Fastlane2on Mar 07, 2013 9:10pm
154 Views
Post# 21097319

RE: RE: NIOGOLD COMPLETES $2.5 FINANCING

RE: RE: NIOGOLD COMPLETES $2.5 FINANCING

I'm going to take a positive spin on this announcement of 2.5 million instead of 4 million and I'm open for the negative view from anyone. I think Niogold has reassurances from Aurizon's leadership that regardless of their companies  outcome (Aurizon's take-out from Hecla or Alamos) that Niogold's progress with Marban will continue with the new owners. I believe in what management has delivered to date and also believe that internal talks have prevented them from doing more flow through shares...agree or disagree? GL.

Fastlane

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities